Cerev­el notch­es Phase 3 Parkin­son's win ahead of Ab­b­Vie trans­ac­tion clos­ing

As it waits for its ac­qui­si­tion by Ab­b­Vie to fi­nal­ize, Cerev­el re­port­ed a Phase 3 win for one of its pro­grams in Parkin­son’s dis­ease.

Pa­tients tak­ing the biotech’s once-dai­ly drug, called tava­padon, on top of the al­ready ap­proved Parkin­son’s treat­ment lev­odopa saw a sta­tis­ti­cal­ly sig­nif­i­cant in­crease of 1.1 more hours of “on” time com­pared to place­bo, ac­cord­ing to an ear­ly Thurs­day press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER